en · de · es · pt
cjc-1295-notes.peptides3081.com › Wiki › Background And Molecular Design — Quick Reference

Background And Molecular Design — Quick Reference

By Editorial Desk · published 2026-05-15 · last reviewed 2026-06-15 · Wiki

If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Cjc-1295 at a glance

PropertyValueNotes
Duration with linkerSeveral daysReported in early human work
Duration without linkerTens of minutesShort plasma residence
Albumin attachment siteCysteine-34Covalent maleimide reaction
Primary receptorPituitary GHRH receptorStimulates growth hormone release
Downstream markerInsulin-like growth factor 1Indirect measure of activity

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Related pages on this site

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Reference notes

=== Psychiatry === Suvorexant has been studied in the treatment of insomnia in people with psychiatric disorders such as depression and anxiety. It was reported to improve psychiatric symptoms and to decrease cortisol levels in these individuals. A phase IV clinical trial of suvorexant as an adjunct to antidepressant therapy in people with major depressive disorder and residual insomnia was underway as of 2019. Although orexin receptor antagonists including suvorexant could be useful for treatment of depression and anxiety, there is also indication that they could have harmful effects in these conditions (e.g., animal studies and suicidal ideation in clinical trials). More clinical research is needed to determine the place of orexin receptor antagonists in the treatment of people with depression and anxiety. There is interest in suvorexant and other orexin receptor antagonists in the potential treatment of substance use disorders, including alcohol use disorder, cocaine use disorder, and opioid use disorder.

=== Cell membrane === The urothelium is the most impermeable membrane in the mammalian body. Because of its importance in acting as an osmotic barrier between the contents of the urinary tract and the surrounding organs and tissues, transitional epithelium is relatively impermeable to water and salts. This impermeability is due to a highly keratinized cellular membrane synthesized in the Golgi apparatus. The membrane is made up of a hexagonal lattice put together in the Golgi apparatus and implanted into the surface of the cell by reverse pinocytosis, a type of exocytosis. The cells in the superficial layer of the transitional epithelium are highly differentiated, allowing for maintenance of this barrier membrane. The basal layer of the epithelium is much less differentiated; however, it does act as a replacement source for more superficial layer. While the Golgi complex is much less prominent in the cells of the basal layer, these cells are rich in cytoplasmic proteins that bundle together to form tonofibrils. These tonofibrils converge at hemidesmosomes to attach the cells at the basement membrane.

The first season of Beast Games, a reality competition show created by Jimmy "MrBeast" Donaldson was first released on Amazon Prime Video on December 19, 2024 and concluded on February 13, 2025. Jeffrey Randall Allen won the season, defeating Twana Barnett. Allen won a total grand prize of $10,000,000.

=== Ethiopian relationship === In 1974 a military-led revolution installed a new regime in Ethiopia. For several years the CLP maintained relations with Ethiopian political activists and wrote reports and articles on developments in Ethiopia and Africa. The Soviet Union supported the new Ethiopian government. However, the CLP was critical of Soviet policies. Given the close relationship between the Ethiopian government and the Soviet Union, the CLP position in Ethiopia was quite precarious. Eventually the CLP had to leave and return to the US.

=== Reproductive output === While the average weight of females does not differ between high and low-density population conditions reproductive output is greater in low-density conditions compared to high-density conditions. Females in high-density conditions also experience a higher mortality rate. In a study by Wall and Begon (1987) 10 of 29 females in high-density conditions died while no females died in the low-density conditions. A positive correlation also exists between the number of eggs per pod and the length of a female's hind femur. Females in high-density conditions produced only half of the eggs produced by females in low-density conditions. Larger females in high-density conditions produce eggs at a faster rate than smaller females. While smaller females in low-density groups produce eggs faster than larger females resulting in an equal reproductive output between small and large females.

Sources: en.wikipedia.org

Notes from published material

In January 2024, a preliminary review conducted by the US Food and Drug Administration (FDA) confirmed no evidence had been found to suggest that the medicine causes suicidal thoughts or actions. In June 2025, the European Medicines Agency recommended that the product information for semaglutide medicines be updated to include non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect, while the World Health Organization concluded that the risk management plan for semaglutide should be revised to include NAION as a potential risk. A 2025 observational study reported a modest increased risk of a serious eye condition in people with diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists. The analysis found that individuals using the medications had a slightly higher incidence of neovascular age-related macular degeneration compared to similar individuals not on the medications. In the STEP-HFpEF trial including people with obesity and heart failure with preserved ejection fraction, weight loss was associated with improvements in heart failure symptoms and functional capacity. An observational study on people with obesity and type 2 diabetes and heart failure with preserved ejection fraction, semaglutide had about a 42% lower risk of hospitalization for heart failure and all-cause death combined compared with sitagliptin.

== History of the term == Homochirality was introduced by Lord Kelvin in 1904, the year that he published his Baltimore Lecture of 1884. Kelvin used homochirality as a relationship between two molecules, i.e. two molecules are homochiral if they have the same chirality. Homochiral has been used in the same sense as enantiomerically pure. This is permitted in some journals (but not encouraged), its meaning in these journals being the preference of a process or system for a single optical isomer of a pair.

Elastic fibers are found in the skin, lungs, arteries, veins, connective tissue proper, elastic cartilage, periodontal ligament, fetal tissue and other tissues which must undergo mechanical stretching. In the lung there are thick and thin elastic fibers. Elastic fibers are absent from scarring, keloids and dermatofibromas and they are decreased greatly, or are absent in anetodermas.

=== Cancer progression, tumor characterization === The mammographic density is correlated with the collagen density, thus SHG can be used for identifying breast cancer. SHG is usually coupled to other nonlinear techniques such as Coherent anti-Stokes Raman Scattering or Two-photon excitation microscopy, as part of a routine called multiphoton microscopy (or tomography) that provides a non-invasive and rapid in vivo histology of biopsies that may be cancerous.

Sources: en.wikipedia.org

Background from the literature

He influenced the works of Francis Bacon, René Descartes, Giordano Bruno, Tommaso Campanella and Thomas Hobbes. In 1602 Campanella wrote his most famous work, The City of the Sun and later defended Galileo Galilei during his first trial with his work A Defense of Galileo, which was published in 1622. In 1613 philosopher and economist Antonio Serra wrote A Short Treatise on the Wealth and Poverty of Nations and was a pioneer in the Mercantilist tradition. Calabria was important to the Spanish monarchs beginning in the reign of Emperor Charles V of Habsburg, who held the title of King of Naples, as when the sovereign granted royal privileges to Catanzaro. The city had resisted the 28 August 1528 siege by a French army supported by some FrancophileCalabrian and Apulian nobles. In gratitude, Charles V granted the city the right to use the imperial eagle as its symbol, exempted it from royal tributes and gave it the power to mint coins worth one carlin. The emperor personally visited the region in 1535 on his return from the capture of Tunis, where, at the command of a fleet of as many as 500 ships, he had defeated the Ottoman army and freed 20,000 Christian slaves. After the African conquest, Charles V landed in Sicily and then in Calabria. Having passed Aspromonte, he visited Nicastro, Martirano, Carpanzano, Rogliano, Tessano and Cosenza. From there the monarch passed through Bisignano, Castrovillari and Laino, and continued to Naples. During Spanish rule in Calabria, many towns tried to defend themselves from Saracen raids.

== Arrival in Spain == In Madrid, Alexander von Humboldt pursued the idea of a scientific expedition to Spanish America, despite the usual restrictions on foreign travel in Spanish colonies. Through the assistance of Don Mariano Luis de Urquijo, Spain’s First Secretary of State, whom Humboldt had previously met in London, he was introduced to King Charles IV of Spain. The king granted Humboldt and his companion, Aimé Bonpland, official permission to travel throughout Spanish America for scientific purposes. The royal passports granted Humboldt and Bonpland extensive rights, including the use of scientific instruments, freedom of movement, and the authority to conduct research throughout Spanish territories. Colonial officials were instructed to assist them as needed. Such privileges were exceptional, given that Spain had historically allowed very few foreign scientific missions in its colonies, due to longstanding policies of restricting access to outsiders for reasons of state security, economic monopoly, and religious protection. The level of trust and freedom granted to Humboldt was unprecedented for a non-Spaniard. Humboldt recognized that Spain’s primary interest in granting permission was related to his expertise in mineralogy and the potential for discovering new mineral resources, rather than purely scientific advancement.

== Pharmacokinetics == With the once-monthly formulation of paliperidone palmitate, the time to peak is 13 days and the elimination half-life is 25 to 49 days; for the 3-month formulation, the time to peak is 30 to 33 days and the half-life is 84 to 95 days (deltoid muscle) or 118 to 139 days (gluteal). These data come from a 2021 review whose authors included employees of Janssen Research & Development, the manufacturer of paliperidone palmitate. The peak-to-trough ratio of paliperidone palmitate at steady state ranges from 1.56 to 1.70 with the 1- and 3-month formulations. No pharmacokinetic data for the 6-month formulation has been released as of January 2021. However, a 2025 case report described a patient who still had measurable plasma paliperidone concentrations in the low therapeutic range 886 days (2.5 years) after her last injection, indicating that in some individuals the drug may be released from the depot far longer than the predicted half‑life. The pharmacokinetic profile was originally derived from a 2009 pooled analysis of 18,530 paliperidone concentration samples from 1,795 subjects across six Phase I trials and five Phase II and III trials funded by Johnson & Johnson Pharmaceutical Research and Development, LLC. Invega Sustenna, Invega Trinza, and Invega Hafyera all utilize nanoparticle technology. The NanoCrystal® technology used in all three long-acting paliperidone products is manufactured by Alkermes plc.

Sources: en.wikipedia.org

Frequently asked questions

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Does the modification change how the peptide signals?

The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.

Are human half-life figures well established?

Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.

Why is mass spectrometry used alongside chromatography?

Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.

Network